- Home
- IFIN vs XFOR Comparison
IFIN vs XFOR Comparison
Compare IFIN & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFIN
- XFOR
- Stock Information
- Founded
- IFIN 2021
- XFOR 2014
- Country
- IFIN United States
- XFOR United States
- Employees
- IFIN N/A
- XFOR N/A
- Industry
- IFIN Business Services
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IFIN Consumer Discretionary
- XFOR Health Care
- Exchange
- IFIN Nasdaq
- XFOR Nasdaq
- Market Cap
- IFIN 118.3M
- XFOR 115.8M
- IPO Year
- IFIN 2021
- XFOR N/A
- Fundamental
- Price
- IFIN N/A
- XFOR $0.65
- Analyst Decision
- IFIN
- XFOR Buy
- Analyst Count
- IFIN 0
- XFOR 3
- Target Price
- IFIN N/A
- XFOR $3.67
- AVG Volume (30 Days)
- IFIN 12.0K
- XFOR 891.3K
- Earning Date
- IFIN 01-01-0001
- XFOR 08-08-2024
- Dividend Yield
- IFIN N/A
- XFOR N/A
- EPS Growth
- IFIN 87.83
- XFOR N/A
- EPS
- IFIN N/A
- XFOR 0.09
- Revenue
- IFIN N/A
- XFOR $563,000.00
- Revenue This Year
- IFIN N/A
- XFOR N/A
- Revenue Next Year
- IFIN N/A
- XFOR $635.10
- P/E Ratio
- IFIN N/A
- XFOR $7.55
- Revenue Growth
- IFIN N/A
- XFOR N/A
- 52 Week Low
- IFIN $4.98
- XFOR $0.53
- 52 Week High
- IFIN $13.59
- XFOR $1.60
- Technical
- Relative Strength Index (RSI)
- IFIN 14.96
- XFOR 41.38
- Support Level
- IFIN $10.58
- XFOR $0.64
- Resistance Level
- IFIN $10.35
- XFOR $0.69
- Average True Range (ATR)
- IFIN 0.98
- XFOR 0.05
- MACD
- IFIN -1.12
- XFOR -0.00
- Stochastic Oscillator
- IFIN 0.00
- XFOR 14.09
About IFIN InFinT Acquisition Corporation
Infint Acquisition Corp is a blank check company.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.